Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 2;14(3):775. doi: 10.3390/cancers14030775

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

SSTR2 immunoreactivity was evaluated by three different scoring systems and their correlation with the therapeutic efficacy of SSAs in Group 3 patients. (a–c) The area under the curve (AUC) was highest when evaluated using DIA (AUC, 0.65; cut-off, 898.945; sensitivity, 80%; specificity, 75%), compared with that when using Volante scores (AUC, 0.6125; cut-off, 2; sensitivity, 90%; specificity, 25%) and IRSs (AUC, 0.5875; cutoff, 4; sensitivity, 70%; specificity, 50%). (d–f) Higher proportions of SD or CR were detected in positive cases than in negative cases regardless of the scoring systems used. (f) SSTR2 immunoreactivity evaluated by DIA tended to be closely associated with the therapeutic efficacy of SSAs, but not when evaluated using the Volante scores and IRSs.